Kairos Pharma (KAPA) vs Mustang Bio (MBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Mustang Bio is the larger company by market cap ($3.0 million vs $2.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KAPA | MBIO |
|---|---|---|
| Share price | $0.8103 | $0.4001 |
| Market cap | $2.74M | $3.03M |
| 1-day change | -15.55% | -2.44% |
| EPS (TTM) | $-1.66 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.24 | $1.81 |
| 52-week low | $0.7827 | $0.3802 |
| Distance from 52-week high | -91.23% | -77.90% |
| Analyst consensus | none | — |
| Avg. price target upside | +5947.14% | — |
| Average volume | 602.89K | 29.38K |
| Shares outstanding | 3.39M | 6.73M |
| Employees | 1 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kairos Pharma
KAPA stock →Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About Mustang Bio
MBIO stock →Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
KAPA vs MBIO FAQ
Which is bigger, Kairos Pharma or Mustang Bio?
Mustang Bio (MBIO) is larger, with a market capitalization of $3.03M compared with $2.74M for Kairos Pharma (KAPA).
Are Kairos Pharma and Mustang Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.